StratX™
Lung Analysis Platform
TREAT WITH CONFIDENCE
StratX™ Lung Analysis Platform

A cloud-based quantitative CT analysis service that supports endobronchial valve (EBV) patient selection and treatment targeting by providing clinically-validated information on emphysema destruction, fissure completeness and lobar volumes.

> Pulmonx EBV therapy is the most rigorously studied minimally-invasive treatment for severe emphysema and is proven to improve patients’ breathing function, exercise capacity and quality of life.¹

Accuracy in identifying EBV responders and non-responders when combined with selective use of the Chartis Pulmonary Assessment System²

Easy to Identify Patients Most Likely to Benefit from EBV therapy

Clinically-Validated and Consistent across CT Scanners and hospitals²

---

SUMMARY
Illustration summarizes key information

RESULTS
Table lists validated measurements by lobe:
- Fissure completeness
- Emphysema density (based on voxel density less than -910 HU)
- Inspiratory volume

---

USER-FRIENDLY DESIGN
for clear interpretation and ease of use
**CLINICALLY-VALIDATED ALGORITHM**

for fissure completeness

**OPTIMAL APPROACH**

The StratX analysis combined with selective use of the Chartis system results in higher accuracy than when either diagnostic tool is used alone.2

1. Assess all potential EBV patients with the StratX analysis.
2. For patients in which the StratX analysis identified partially complete fissures, proceed with a Chartis assessment.
3. Patients with complete fissures or identified with the Chartis assessment as CV- can receive EBV therapy.

The StratX analysis quantifies the completeness of each fissure using an algorithm that has been validated in a retrospective study of over 200 EBV patients, the largest such analysis performed to date.2 Fissure completeness is a proven predictor for volume reduction resulting from EBV therapy.3

---

**Table: StratX Analysis Results**

<table>
<thead>
<tr>
<th>% Fissure Completeness</th>
<th>RUL</th>
<th>RUL+RML</th>
<th>RML</th>
<th>RLL</th>
</tr>
</thead>
<tbody>
<tr>
<td>64.2</td>
<td>65.0</td>
<td>84.9</td>
<td>65.0</td>
<td>100</td>
</tr>
</tbody>
</table>

**Key: EBV Therapy**

- Complete Fissures (≥95% complete)
- Partially Complete Fissures (80-95% complete)
- Incomplete Fissures (<80% complete)

**EBV Therapy**

- CV-: Do Not Treat with EBV Therapy
- CV+: Proceed with EBV Therapy
WORKFLOW WITH RAPID TURNAROUND TIME

1. Capture CT Scan
Capture a high resolution chest CT scan according to the StratX CT parameters.

2. Upload CT Scan
Use web browser to upload CT scan to the secure, cloud-based StratX platform.
- Automatically anonymized data with no patient health information transfer
- Secure 256 bit SSL socket level encryption

3. Analyze Data + Generate Report
Data is analyzed by validated algorithms and the StratX report is uploaded to the StratX platform within 2-3 working days.

4. Review Report
Access pulmonxstratx.com to review the report in a .pdf (2D) or .html (3D) format from any clinical setting.

5. Confidently Determine Treatment Options
Determine the most suitable treatment option for your patient using the quantitative StratX information and clinical judgment.

Disclaimer: Report contains quantitative assessment only and should not be construed as a complete radiological analysis.

CE XXXXX. Powered by Thirona LungQ v1.0.0

Page 1 of 3
StratX™
Lung Analysis Platform enables you to:

1. Potentially offer EBV therapy to more patients
2. Non-invasively screen treatment candidates
3. Chose between multiple potential treatment targets if applicable
4. Enhance case planning and optimize procedure time
5. Compare quantitative analyses across patients
6. Educate referrers about the optimal candidate for EBV therapy
7. Educate patients using user-friendly reports
8. Support compliance and good documentation practices

Contact us for more information: info@pulmonxstratx.com

Visit our website: www.pulmonx.com

REFERENCES:
3 Reymond et al. AJR Am J Roentgenol. 2013 Oct; 201(4)